Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Interferon alfacon-1

Drug Profile

Interferon alfacon-1

Alternative Names: Advaferon; CIFN; IFN-consensus; Infarex; Infergen; Interferon consensus; Interferon-alpha con1; Interferon-alpha consensus; rConINF; Recombinant consensus interferon; Recombinant methionyl interferon consensus; YM 643

Latest Information Update: 23 Sep 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Amgen
  • Developer Astellas Pharma; Three Rivers Pharmaceuticals
  • Class Antineoplastics; Antivirals; Interferons
  • Mechanism of Action Immunostimulants; Interferon alpha stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Hepatitis C
  • Discontinued Cancer; Non-Hodgkin's lymphoma; Ovarian cancer; Severe acute respiratory syndrome

Most Recent Events

  • 25 Oct 2010 Three Rivers Pharmaceuticals has been acquired by Kadmon Pharmaceuticals
  • 07 Jul 2010 Registered for retreatment of Hepatitis C in combination with ribavirin in USA (SC)
  • 16 Jun 2009 Final efficacy data from the DIRECT trial in Hepatitis C released by Three Rivers
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top